drugset / Trial / NCT00561522
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
Timeline
- Start
- 2007-11
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |